The following institutions and persons participated in the Asia Hepatitis Lamivudine Study Group: Prince of Wales Hospital, Hong Kong, China—Dr. Steven Tsang; University of Hong Kong, China—Dr. Man-Fung Yuen, Dr. Wai-Man Wong; National Cheng Kung University Hospital, Tainan, Taiwan—Dr. Ai-Wen Kao; Chang Gung Memorial Hospital, Kaohsiung Hsein, Taiwan—Ms. Chiu-Jung Chen; Singapore General Hospital—Dr. Khoon-Beng Chuah, Dr. Han-Seong Ng.
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
Article first published online: 30 DEC 2003
Copyright © 2001 American Association for the Study of Liver Diseases
Volume 33, Issue 6, pages 1527–1532, June 2001
How to Cite
Leung, N. W. Y., Lai, C.-L., Chang, T.-T., Guan, R., Lee, C.-M., Ng, K.-Y., Lim, S.-G., Wu, P.-C., Dent, J. C., Edmundson, S., Condreay, L. D. and Chien, R.-N. (2001), Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology, 33: 1527–1532. doi: 10.1053/jhep.2001.25084
- Issue published online: 30 DEC 2003
- Article first published online: 30 DEC 2003
- Glaxo Wellcome Research and Development, Greenford, UK
A study in Chinese patients with chronic hepatitis B showed that treatment with lamivudine for 1 year significantly improves liver histology and enhances hepatitis B e antigen (HBeAg) seroconversion compared with placebo. Fifty-eight patients from this 1-year study have received long-term treatment with lamivudine 100 mg; the outcome of 3 years of lamivudine is reported here. Before treatment, all patients had detectable HBeAg. HBeAg seroconversion (HBeAg-negative, anti-HBe–positive), hepatitis B virus (HBV)-DNA suppression, alanine transaminase (ALT) normalization, emergence of YMDD variant HBV, liver histology, and long-term safety were assessed. After 3 years of continuous treatment with lamivudine 100 mg daily, 40% (23 of 58) of patients achieved HBeAg seroconversion. In patients with baseline serum ALT >2× upper limit of normal (ULN), the rate of HBeAg seroconversion was 65% (17 of 26). Median serum HBV-DNA concentrations were below the level of detection, and median ALT concentrations were within the normal range throughout 3 years of treatment. YMDD variant HBV emerged in 33 of 58 (57%) patients during the 3 years, of whom 9 (27%) achieved HBeAg seroconversion (6 after emergence of YMDD variant HBV). ALT levels and histologic scores after emergence of YMDD variant HBV did not show major deterioration. Lamivudine was well tolerated during 3 years of therapy. In conclusion, these data in Chinese patients with chronic hepatitis B show enhanced seroconversion rates with extended lamivudine treatment. Up to two thirds of patients with moderately elevated pretreatment ALT achieved HBeAg seroconversion after 3 years of therapy.